hi INDiA
South Asian Views On Global News - Update 24X7

NTAGI to review data on 1st cervical cancer vaccine

New Delhi, June 26

The National Technical Advisory Group on Immunisation (NTAGI) will on Tuesday review clinical trial data on India’s first cervical cancer vaccine developed by the Serum Institute of India. The first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, namely, CERVAVAC has been in the works for some time now.

The NTAGI will take a call on whether the shot is useful enough for inclusion in the national immunisation programme. To this end, a group on HPV under the apex vaccine body had on June 8 looked at the clinical trial data of the vaccine, with NTAGI to take the final decision.

The SII recently wrote to the national regulator, the Drugs Controller General of India, seeking market authorisation for the vaccine following the completion of late stage phase 2/3 trials in collaboration with the Department of Biotechnology.

The subject expert committee of the national drug regulator had on June 15 granted market authorisation to the jab with the DCGI nod awaited.

Visa-Home Ad

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

gtag('set', {'user_id': 'USER_ID'}); // Set the user ID using signed-in user_id.